Primary biliary cirrhosis: Report of a focus study group

Hepatology

Volumn 40, Issue 4, 2004, Pages 1013-1020

  Bergasa, Nora V ^a   Mason, Andrew ^b   Floreani, Annarosa ^c   Heathcote, Jenny ^d   Swain, Mark G ^e   Jones, David E J ^f   Lindor, Keith M ^g   Bassendine, Margaret F ^f   Worman, Howard J ^h  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF CALGARY   (Canada)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

^g MAYO CLINIC   (United States)

^h Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SELECTIVE ESTROGEN RECEPTOR MODULATOR;

DETERIORATION; FATIGUE; HUMAN; IMMUNOGENETICS; NONHUMAN; PATHOPHYSIOLOGY; PREDICTION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RETROVIRUS; REVIEW; VIRUS IDENTIFICATION;

EID: 4644305041     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.1840400434     Document Type: Review

References (78)

1. Kita H, Nalbandian G, Keeffe E, Coppel RL, Gershwin ME. Pathogenesis of primary biliary cirrhosis. Clin Liver Dis 2003;7:821-839.
2. Xu L, Shen Z, Guo L, Fodera B, Keogh A, Joplin R, et al. Does a betaretrovirus infection trigger primary biliary cirrhosis? Proc Natl Acad Sci U S A 2003;100:8454-8459.
3. Xu L, Sakalian M, Shen Z, Loss G, Neuberger J, Mason A. Cloning the human betaretrovirus proviral genome from patients with primary biliary cirrhosis. HEPATOLOGY 2004;39:151-156.
4. Pogo BG, Holland JF. Possibilities of a viral etiology for human breast cancer. A review. Biol Trace Elem Res 1997;56:131-142.
5. Buetti E, Diggelmann H. Cloned mouse mammary tumor virus DNA is biologically active in transfected mouse cells and its expression is stimulated by glucocorticoid hormones. Cell 1981;23:335-345.
6. Mason A, Nair S. Primary biliary cirrhosis: new thoughts on pathophysiology and treatment. Curr Gastroenterol Rep 2002;4:45-51.
7. Sadamoto T, Joplin R, Keogh A, Mason A, Carman W, Neuberger J. Expression of pyruvate-dehydrogenase complex PDC-E2 on biliary epithelial cells induced by lymph nodes from primary biliary cirrhosis. Lancet 1998;352:1595-1596.
8. Baragiotta A, Agarwal K, Floreani A, Venturi C, Donaldson P, Bassendine M. Is the cytotoxin T lymphocyte-associated antigen-4 (CTLA-4) gene polymorphism a susceptibility locus for primary biliary cirrhosis [abstract]? Gut 2001;49(Suppl 3).
9. Donaldson P, Agarwal K, Craggs A, Craig W, James O, Jones D. HLA and interleukin 1 gene polymorphisms in primary biliary cirrhosis: associations with disease progression and disease susceptibility. Gut 2001;48:397-402.
10. Stone J, Wade JA, Cauch-Dudek K, Lindor KD, Heathcote EJ. Human leukocyte antigen class II associations in serum antimitochondrial antibodies (AMA)-positive and AMA-negative primary biliary cirrhosis. J Hepatology 2002;36:8-13.
11. Seki T, Kiyosawa K, Ota M, Furuta S, Fukushima H, Tanaka E, et al. Association of primary biliary cirrhosis with human leukocyte antigen DPB1*0501 in Japanese patients. HEPATOLOGY 1993;18:73-78.
12. Invernizzi P, Battezzati PM, Crosignani A, Perego F, Poli F, Morabito A, et al. Peculiar HLA polymorphisms in Italian patients with primary biliary cirrhosis. J Hepatol 2003;38:401-406.
13. Springer JE, Cole DE, Rubin LA, Cauch-Dudek K, Harewood L, Evrovski J, et al. Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis. Gastroenterology 2000;118:145-151.
14. Vogel A, Strassburg CP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. HEPATOLOGY 2002;35:126-131.
15. Pares A, Guanabens N, Alvarez L, De Osaba MJ, Oriola J, Pons F, et al. Collagen type Ialpha1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis. HEPATOLOGY 2001;33:554-560.
16. Lakatos LP, Bajnok E, Hegedus D, Toth T, Lakatos P, Szalay F. Vitamin D receptor, oestrogen receptor-alpha gene and interleukin-1 receptor antagonist gene polymorphisms in Hungarian patients with primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2002;14:733-740.
17. Springer J, Cauch-Dudek K, O'Rourke K, Wanless IR, Heathcote EJ. Asymptomatic primary biliary cirrhosis: a study of its natural history and prognosis. Am J Gastroenterol 1999;94:47-53.
18. Balasubramaniam K, Grambsch PM, Wiesner RH, Lindor KD, Dickson ER. Diminished survival in asymptomatic primary biliary cirrhosis. A prospective study. Gastroenterology 1990;98:1567-1571.
19. Shapiro JM, Smith H, Schaffner F. Serum bilirubin: prognostic factor in primary biliary cirrhosis. Gut 1979;20:137-140.
20. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langwhorthy A. Prognosis in primary biliary cirrhosis: a model for decision making. HEPATOLOGY 1989;10:1-7.
21. Zuchner D, Sternsdorf T, Szostecki C, Heathcote E, Cauch-Dudek K, Will H. Prevalence, kinetics and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis. HEPATOLOGY 1997;5:1123-1130.
22. Joshi S, Cauch-Dudek K, Heathcote EJ, Lindor K, Jorgensen R, Klein R. Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis? Am J Gastroenterol 2002;97:999-1002.
23. Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Eng J Med 1983;308:1-7.
24. Corpechot C, Carrat F, Poupon R, Poupon RE. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 2002;122:652-658.
25. Vleggaar FP, van Burren HR, Zondervan PE, ten Kate FJW, Hop WCJ; group TDMPs. Jaundice in non-cirrhotic primary biliary cirrhosis: the premature ductopenic variant. Gut 2001;49:276-281.
26. Cauch-Dudek K, Abbey S, Stewart DE, Heathcote EJ. Fatigue in primary biliary cirrhosis. Gut 1998;43:705-710.
27. Blatteis CM. The afferent signalling of fever. J Physiol 2000;526(Pt 3): 470.
28. Konsman JP, Luheshi GN, Bluthe RM, Dantxer R. The vagus nerve mediates behavioural depression, but not fever, in response to peripheral immune signals; a functional anatomical analysis. Eur J Neurosci 2000;12:4434-4446.
29. Gaykema RP, Dijkstra I, Tilders FJ. Subdiaphragmatic vagotomy suppresses endotoxin-induced activation of hypothalamic corticotropin-releasing hormone neurons and ACTH secretion. Endocrinology 1995;136:4717-4720.
30. Turnbull AV, Rivier CL. Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev 1999;79:1-71.
31. Swain MG. Fatigue in chronic disease. Clin Sci (Lond) 2000;99:1-8.
32. Beam J, Wessely S. Neurobiological aspects of the chronic fatigue syndrome. Eur J Clin Invest 1994;25:79-90.
33. Swain MG, Maric M. Improvement in cholestasis-associated fatigue with a serotonin receptor agonist using a novel rat model of fatigue assessment. HEPATOLOGY 1997;25:291-294.
34. Burak KW, Le T, Swain MG. Increased sensitivity to the locomotor-activating effects of corticotropin-releasing hormone in cholestatic rats. Gastroenterology 2002;122:681-688.
35. Goldblatt J, Taylor PJ, Lipman T, Prince MI, Baragiotta A, Bassendine MF, et al. The true impact of fatigue in primary biliary cirrhosis: a population study. Gastroenterology 2002;122:1235-1241.
36. Talbot TL, Schmitt JM, Bergasa NV, Jones EA, Walker EC. Application of piezo film technology for the quantitative assessment of pruritus. Biomed Instrum Techn 1991;25:400-403.
37. Rannard A, Buck D, Jones DEJ, James OFW, Jacoby A. Assessing quality of life in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2004;2:162-174.
38. Heathcote EJ. Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. HEPATOLOGY 2000;31:1005-1013.
39. Yeaman SJ, Fussey SP, Danner DJ, James OF, Mutimer DJ, Bassendine MF. Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens. Lancet 1988;1:1067-1070.
40. Suzuki A, Van de Water J, Gershwin ME, Jorgensen R, Angulo P, Lindor K. Oral tolerance and pyruvate dehydrogenase in patients with primary biliary cirrhosis. Dev Immunol 2002;9:55-61.
41. Wu HY, Weiner HL. Oral tolerance. Immunol Res 2003;28:265-284.
42. Abdulkarim AS, Petrovic LM, Kim WR, Angulo P, Lloyd RV, Lindor KD. Primary biliary cirrhosis: an infectious disease caused by Chlamydia pneumoniae? J Hepatol 2004;40:380-384.
43. Maddala YK, Jorgensen RA, Angulo P, Lindor KD. Open-label pilot study of tetracycline in the treatment of primary biliary cirrhosis. Am J Gastroenterol 2004;99:566-567.
44. Luper S. A review of plants used in the treatment of liver disease: part 1. Altern Med Rev 1998;3:410-421.
45. Luper S. A review of plants used in the treatment of liver disease: part two. Altern Med Rev 1999;4:178-188.
46. Angulo P, Patel T, Jorgensen RA, Therneau TM, Lindor KD. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. HEPATOLOGY 2000;32:897-900.
47. Vosper H, Khoudoli GA, Graham TL, Palmer CN. Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis. Pharmacol Ther 2002;95:47-62.
48. Chianale J, Vollrath V, Wielandt AM, Amigo L, Rigotti A, Nervi F, et al. Fibrates induce mdr2 gene expression and biliary phospholipid secretion in the mouse. Biochem J 1996;314(Pt 3):781-786.
49. Peters JM, Aoyama T, Burns AM, J. GF. Bezafibrate is a dual ligand for PPARalpha and PPARbeta: studies using null mice. Biochim Biophys Acta 2003;1632:80-89.
50. Kanda T, Yokosuka O, Imazeki F, Saisho H. Bezafibrate treatment: a new medical approach for PBC patients? J Gastroenterol 2003;38:573-578.
51. O'Connell EJ. Review of the unique properties of budesonide. Clin Ther 2003;25(Suppl C):C42-C60.
52. Angulo P, Jorgensen RA, Keach JC, Dickson ER, Smith C, Lindor KD. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. HEPATOLOGY 2000;31:318-323.
53. Leuschner M, Maier KP, Schlichting J, Strahl S, Herrmann G, Dahm HH, et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 1999;117:918-925.
54. Allison AC, Eugui EM. Immunosuppressive and long-acting anti-inflammatory activity of mycophenolic acid and derivative, RS-61443. Br J Rheumatol 1991;30(Suppl 2):57-61.
55. Jones EA, ten Kate FJ, ter Borg F, Houben M, Reesink HW, Chamuleau RA. Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999;11:1165-1169.
56. Altschuler EL. Mycophenolate mofetil for primary biliary cirrhosis-convergent thinking. Eur J Gastroenterol Hepatol 2000;12:587.
57. Angulo P, Jorgensen RA, Lindor KD. Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid. Gastroenterology 2003;124:A784.
58. Bolder U, Trang NV, Hagey LR, Schteingart CD, Ton-Nu HT, Cerre C, et al. Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats. Gastroenterology 1999;117:962-971.
59. Leuschner M, Holtmeier J, Ackermann H, Leuschner U. The influence of sulindac on patients with primary biliary cirrhosis that responds incompletely to ursodeoxycholic acid: a pilot study. Eur J Gastroenterol Hepatol 2002;14:1369-1376.
60. Reddy A, Prince M, James OF, Jain S, Bassendine MF. Tamoxifen: a novel treatment for primary biliary cirrhosis? Liver Int 2004;24:194-197.
61. McDonnell DP, Chang CY, Norris JD. Capitalizing on the complexities of estrogen receptor pharmacology in the quest for the perfect SERM. Ann N Y Acad Sci 2001;949:16-35.
62. Alvaro D, Alpini G, Onori P, Perego L, Svegliata Baroni G, Franchitto A, et al. Estrogens stimulate proliferation of intrahepatic biliary epithelium in rats. Gastroenterology 2000;119:1681-1691.
63. Alvaro D, Onori P, Metalli VD, Svegliati-Baroni G, Folli F, Franchitto A, et al. Intracellular pathways mediating estrogen-induced cholangiocyte proliferation in the rat. HEPATOLOGY 2002;36:297-304.
64. Alvaro D, Alpini G, Onori P, Franchitto A, Glaser S, Le Sage G, et al. Effect of ovariectomy on the proliferative capacity of intrahepatic rat cholangiocytes. Gastroenterology 2002;123:336-344.
65. Alvaro D, Invernizzi P, Onori P, Franchitto A, Pinto G, De Santis A, et al. Expression of estrogen receptors in cholangiocytes of patients with primary biliary cirrhosis (PBC) and relationship with immunohistochemical markers of cell proliferation and death. J Hepatol 2003;2003(Suppl 2):38.
66. Goodwin B, Redinbo MR, Kliewer SA. Regulation of CYP3A gene transcription by the pregnane X receptor. Annu Rev Pharmacol Toxicol 2002;42:1-23.
67. Desai PB, Nallani SC, Sane RS, Moore LB, Goodwin BJ, Buckley DJ, et al. Induction of cytochrome P450 3A4 in primary hepatocytes and activation of the human pregnane X receptor by Tamoxifen and 4-hydroxytamoxifen. Drug Metab Dispos 2002;30:608-612.
68. Iwasaki S, Tsuda K, Ueta H, Aono R, Ono M, Saibara T, et al. Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis. Hepatol Res 1999;16:12-18.
69. Yano K, Kato H, Morita S. Long-term administration of bezafibrate on primary biliary cirrhosis. Acta Hepatologica Japonica 2002;43:115-120.
70. Kurihara T, Maeda A, Shigemoto M, Yamashita K, Hashimoto E. Investigation into the efficacy of bezafibrate against primary biliary cirrhosis with histological references from long term monotherapy. Am J Gastroenterol 2002;97:212-214.
71. Yano K, Kato H, Morita S, Takahara O, Ishibashi H, Furukawa R. Is bezafibrate histologically effective for primary biliary cirrhosis? Am J Gastroenterol 2002;97:1075-1077.
72. Ohira H, Sato Y, Ueno T, Sata M. Fenofibrate treatment in patients with primary biliary cirrhosis. AmJ Gastroenterol 2002;97:2147-2149.
73. Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002;123:1044-1051.
74. Nakai S, Masaki T, Kurokohchi K, Deguchi A, Nishioka M. Combination therapy of bezafibrate and ursodeoxycholic acid in primary biliary cirrhosis: a preliminary study. Am J Gastroenterol 2000;95:326-327.
75. Kliewer SA, Willson TM. Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor. J Lipid Res 2002;43:359-364.
76. Billingham RE, Brent L, Medawar PB. Activity acquired tolerance of foreign cells. Nature 1953;172:603-606.
77. Medawar P. Available at: http://www.nobel.se/medicine/laureates/1960/ medawar-lecture.html. Accessed: September 8, 2004.
78. Pauli-Magnus C, Kerb R, Fattinger K, Lang T, Anwald B, Kullak-Ublick GA, et al. BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. HEPATOLOGY 2004;39:779-791.